Exelixis

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exelixis reports robust Q4 performance, eyes pipeline expansion in 2023

Exelixis showed strong revenue growth and strategic wins in Q4 2022.
The company faces challenges with net losses and gross to net expectations.
Opportunities lie in pipeline advancement, zanzalintinib development, and new business activities.
Overall, Exelixis remains focused on growth and innovation in the pharmaceutical sector.

Exelixis reports strong Q1 earnings, advances promising pipeline programs

Exelixis showcased robust financials and a promising pipeline in Q1, driven by strong CABOMETYX performance and R&D advancements.
Challenges include gross to net impact and delays in share repurchase program purchases, with key decisions pending on XL102 progress.
Opportunities lie in expanding Phase 3 trials, focusing on unmet needs, and maintaining a strategic approach to asset prioritization for future growth.

Exelixis reports robust Q2 earnings, advances pipeline for growth

Exelixis delivered a strong Q2 performance with significant revenue and income figures, driven by the success of CABOMETYX and ongoing R&D efforts.
The company's market leadership, legal resolution with Teva, and commitment to innovation position it well for future growth and competitive advantage.
While facing challenges in program decision-making and market penetration, Exelixis has opportunities in pipeline advancement, regulatory discussions, and investor engagement.
Overall, Exelixis remains focused on its mission to help cancer patients, with a positive outlook and strategic initiatives in place for continued success.

Exelixis reports strong Q3 earnings, faces guidance challenges and growth opportunities

Exelixis had a strong Q3 2023 with robust revenue growth from CABOMETYX and ongoing operational support.
The company faces challenges in financial guidance adjustments and questions on FDA expectations and legal proceedings.
Opportunities lie in potential growth for CABOMETYX, advancing pipeline assets, and expanding into new indications.
Overall, Exelixis remains focused on innovation, collaboration, and supporting cancer patients with upcoming R&D Day excitement.

Exelixis reports robust 2023 performance, eyes growth through collaborations

Exelixis had a strong financial performance in 2023, driven by the cabozantinib franchise and strategic initiatives.
While facing challenges such as access to therapies and treatment variations, the company is well-positioned for growth.
Opportunities lie in collaborations, regulatory progress, and innovative drug development, positioning Exelixis for future success.

Exelixis reports strong Q1 earnings, focuses on pipeline advancement

Exelixis had a robust Q1 2024 with revenue and demand growth for Cabozantinib franchise.
Company is focused on advancing new indications, returning capital to shareholders, and pipeline development.
Challenges include study criteria, market capture, and capital allocation decisions.
Exciting opportunities lie in Zanza's potential, new combinations, and market growth prospects.

Exelixis excels in Q2 with cabozantinib driving revenue growth

Exelixis delivered a strong Q2 performance driven by cabozantinib franchise. Despite challenges in a competitive landscape, the company's focus on pipeline assets and commercial success presents growth opportunities. With increased revenue guidance and strategic initiatives, Exelixis is poised for continued success.

Exelixis excels in Q3 2024 with revenue growth and increased guidance

Exelixis delivered a strong performance in Q3 2024, marked by revenue growth, profitability, and increased guidance for the full year. The company's financial stability, strategic focus on oncology, and strong cash position provide a solid foundation for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis (EXEL) delivered earnings and revenue surprises of 15.38% and 6.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Q1 Earnings and Revenues Beat Estimates

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Exelixis (EXEL) Q1 Earnings Expected to Decline

TG Therapeutics

Today, we update the investment thesis on two oncology concerns whose stocks have been on fire here in April despite the continued COVID-19 outbreak.

2 Oncology Names That Are 'En Fuego'

AnaptysBio

Key clinical trial results this quarter will determine the better buy.

Better Buy: AnaptysBio vs. Exelixis

Investors are excited about the biotech's positive news from a key late-stage clinical study.

Why Exelixis Stock Is Skyrocketing Today

Exelixis Inc. (NASDAQ: EXEL) stock jumped early on Monday after the company, in conjunction with Bristol-Myers Squibb Co.

Why This Late-Stage Kidney Cancer Study Could Be Huge

Bristol-Myers

Shares of Exelixis Inc. EXEL, +4.91% shot up 8.1%, while Bristil-Myers Squibb Co.

Exelixis, Bristol-Myers stocks get a boost from upbeat trial results of a Kidney cancer treatment

Amazon

Broadcom

Wheaton Precious Metals

Any significant decline in these great companies should be viewed as a gift to investors.

Have $5,000? Then Buy These Top Stocks on Any Coronavirus Weakness

Nektar Therapeutics

New combination trials bring hope for patients and investors.

2 Biotechs Battling Against Kidney Cancer

CRISPR Therapeutics

CRISPR Therapeutics and Exelixis could be excellent long-term picks for your portfolio.

Have An Extra $1,000? Buy These 2 Biotech Stocks

Illumina

EXEL vs. ILMN: Which Stock Is the Better Value Option?

EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?

Kirkland Lake Gold

Investors in these high-quality businesses should be handsomely rewarded for their patience.

3 Top Stocks That Will Make You Richer in Q2 (and Beyond)

Alexion Pharma

Amicus Therapeutics

3 Covid-19 Proof Biotech Stocks

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

Why Is Exelixis (EXEL) Down 15.6% Since Last Earnings Report?

Alphabet

SSR Mining

Skyworks Solutions

The coronavirus crash could crush debt-riddled companies. That's why these cash cows should be on your buy list.

Have $2,500? Then Buy These 4 Cash-Rich Stocks Now

Gilead Sciences

Vertex Pharmaceuticals

These biotechs' profits shouldn't be dented by the COVID-19 pandemic. And their growth prospects appear to be really good.

Coronavirus Crisis: 3 Biotech Stocks to Buy Right Now

Epizyme

Immunomedics

Cancer is one of the most competitive -- and lucrative -- areas for biotech investors.

3 Cancer Treatment Stocks to Buy Right Now

bluebird bio

These three biopharma stocks all ended in positive territory Friday after a week of double-digit declines.

Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday

NuVasive

Natus Medical Inc

The healthcare companies couldn't sidestep the COVID-19 slump.

Here's Why NuVasive, Exelixis, and Natus Medical Fell Today

Barclays

Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at Barclays Global Healthcare Conference 2020 (Transcript)

ACADIA Pharma

Amarin Corporation Plc

Exact Sciences

Jazz Pharmaceuticals

Seagen

Tumultuous market conditions discounted the stock prices of these leading biotech companies.

6 Quality Biotech Stocks on Sale Now

These stocks aren't likely to be infected with the current market worries.

3 Biotech Stocks That Are Coronavirus Safe Havens

Exelixis: Potential Catalysts Ahead For This Mid-Cap Oncology Company

Exelixis' (EXEL) Q4 results are a mixed bag, as earnings beat, while sales marginally miss estimates.

Exelixis (EXEL) Beats on Earnings, Misses on Sales in Q4

Exelixis, Inc. (EXEL) CEO Michael Morrissey on Q4 2019 Results - Earnings Call Transcript

News for Exelixis Stock (EXEL)